A Biologics License Application has been filed for the subcutaneous administration of Rybrevant for some patients with non-small cell lung cancer. A Biologics License Application has been filed with ...
Pretreatment eosinophilia in NSCLC patients is associated with increased immune-related adverse events and reduced progression-free survival when treated with ICIs. The review included 11 ...
TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease ...
GlobalData on MSN
Dizal’s Phase III NSCLC trial of Zegfrovy meets primary endpoint
The open-label trial enrolled patients across 16 countries and regions in Europe, Asia, South America, and North America.
HRQOL is inconsistently evaluated in early-stage NSCLC trials, potentially affecting holistic care approaches. Among 25 trials, HRQOL was not a primary endpoint, appearing as secondary or exploratory ...
Among the 43 evaluable patients treated with sevabertinib, the confirmed objective response rate was 72.1%. The Food and Drug Administration (FDA) has granted Priority Review to the New Drug ...
A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.
Sunvozertinib received FDA priority review for NSCLC with EGFR exon 20 insertion mutations after platinum-based chemotherapy progression. The WU-KONG1 Part B study showed a 53.3% objective response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results